Renalytix AI plc - Asset Resilience Ratio

Latest as of December 2024: 3.64%

Renalytix AI plc (RENX) has an Asset Resilience Ratio of 3.64% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Renalytix AI plc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

GBX417.00K
≈ $50.74 USD Cash + Short-term Investments

Total Assets

GBX11.44 Million
≈ $1.39K USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how Renalytix AI plc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Renalytix AI plc.

Liquid Assets Composition Over Time

This chart breaks down Renalytix AI plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Renalytix AI plc (RENX) long-term investment share to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents GBX0.00 0%
Short-term Investments GBX417.00K 3.64%
Total Liquid Assets GBX417.00K 3.64%

Asset Resilience Insights

  • Limited Liquidity: Renalytix AI plc maintains only 3.64% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Renalytix AI plc Industry Peers by Asset Resilience Ratio

Compare Renalytix AI plc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Singular Health Group Ltd
AU:SHG
Health Information Services 66.96%
Intrasense
PA:ALINS
Health Information Services 15.68%
Medadvisor Ltd
AU:MDR
Health Information Services 12.37%
HITIQ Ltd
AU:HIQ
Health Information Services 30.25%
Pro Medicus Ltd
AU:PME
Health Information Services 54.64%
ARTRYA Ltd
AU:AYA
Health Information Services 32.70%
Cogstate Ltd
AU:CGS
Health Information Services 54.90%
Echoiq Ltd
AU:EIQ
Health Information Services 11.12%

Annual Asset Resilience Ratio for Renalytix AI plc (2012–2025)

The table below shows the annual Asset Resilience Ratio data for Renalytix AI plc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 1.64% GBX100.00K
≈ $12.17
GBX6.10 Million
≈ $742.19
-7.14pp
2024-06-30 8.78% GBX700.00K
≈ $85.17
GBX7.97 Million
≈ $969.96
+7.30pp
2023-12-31 1.48% GBX1.11 Billion
≈ $135.30K
GBX75.27 Billion
≈ $9.16 Million
-1.99pp
2023-06-30 3.47% GBX1.46 Million
≈ $177.64
GBX42.12 Million
≈ $5.12K
-0.87pp
2022-06-30 4.34% GBX2.74 Million
≈ $333.87
GBX63.26 Million
≈ $7.70K
-4.72pp
2021-06-30 9.06% GBX9.29 Million
≈ $1.13K
GBX102.58 Million
≈ $12.48K
+6.68pp
2020-06-30 2.38% GBX982.00K
≈ $119.48
GBX41.30 Million
≈ $5.02K
-1.06pp
2019-06-30 3.44% GBX994.00K
≈ $120.94
GBX28.92 Million
≈ $3.52K
+2.44pp
2016-12-31 1.00% GBX594.67 Million
≈ $72.35K
GBX59.39 Billion
≈ $7.23 Million
-0.14pp
2015-12-31 1.14% GBX647.30 Million
≈ $78.76K
GBX56.80 Billion
≈ $6.91 Million
-0.11pp
2014-12-31 1.25% GBX725.05 Million
≈ $88.22K
GBX58.13 Billion
≈ $7.07 Million
-0.80pp
2013-12-31 2.05% GBX1.29 Billion
≈ $156.50K
GBX62.68 Billion
≈ $7.63 Million
+0.51pp
2012-12-31 1.54% GBX937.44 Million
≈ $114.06K
GBX60.90 Billion
≈ $7.41 Million
--
pp = percentage points

About Renalytix AI plc

LSE:RENX UK Health Information Services
Market Cap
$332.33K
GBX2.73 Billion GBX
Market Cap Rank
#31198 Global
#978 in UK
Share Price
GBX6.25
Change (1 day)
+1.63%
52-Week Range
GBX1.80 - GBX10.75
All Time High
GBX1220.00
About

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more